Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-alphaDC1
- Development stage
- Phase 1
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
CMV-alphaDC1 is an investigational autologous dendritic cell-based vaccine developed by the Roswell Park Comprehensive Cancer Center. It is composed of type 1 polarized dendritic cells (alphaDC1) that have been loaded with peptides derived from the cytomegalovirus (CMV) pp65 protein. The vaccine is designed to prevent CMV reactivation in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. By presenting CMV-specific antigens in a highly immunostimulatory context, CMV-alphaDC1 aims to prime and expand CMV-specific T-cell populations, thereby restoring protective immunity against the virus in the post-transplant period when patients are most vulnerable to opportunistic infections.
- Other names
- CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell VaccineCMV-targeted dendritic cell vaccinealpha-type-1 polarized dendritic cell vaccinationalpha-type1 polarized dendritic cell vaccinationalpha-type 1 polarized dendritic cell vaccination
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on CMV-alphaDC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-alphaDC1.